Studies suggest that gastric neuroendocrine tumors are rare tumors which account for approximately 8% of all neuroendocrine tumors and affect approximately 4 in 100,000 people. The tumor forms in the lining of the gastrointestinal tract and mainly affects people aged 55 to 65. Several new types of treatment are being tested including targeted therapy which uses drugs or other substances to attack specific cancer cells. These studies test new drugs and treatment strategies offering patients access to novel gastric neuroendocrine tumors therapies.
The Gastric Neuroendocrine Tumors Drug Pipeline Report by Expert Market Research gives comprehensive insights into gastric neuroendocrine tumors drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gastric neuroendocrine tumors. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from gastric neuroendocrine tumors.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to gastric neuroendocrine tumors are covered.
Gastrointestinal neuroendocrine tumor is a rare cancerous tumor in neuroendocrine cells of the gastrointestinal tract. These neuroendocrine cells link the nervous system and endocrine system. The common symptoms include stomach pain, diarrhea, nausea and vomiting, unintentional weight loss, jaundice, and fatigue among others. People having multiple endocrine neoplasias and neurofibromatosis type 1 are more likely to develop gastric neuroendocrine tumors. The diagnostic procedures used for the condition include X-rays, computed tomography scans, magnetic resonance imaging, endoscopic ultrasounds, and positron emission tomography scans among others.
There are three grades of neuroendocrine tumors including grade 1 (low-grade tumor), in which cells divide at a low rate, grade 2 (intermediate-grade tumor), in which cells divide at an intermediate rate and grade 3 (high-grade tumor), in which cells divide at a fast rate. There are several ways to treat gastric neuroendocrine tumors such as active surveillance, surgery, and medical treatments. Surgery for tumors depends on the location of tumor and includes partial gastrectomy, small intestine resection, and appendectomy among others. Additionally, the drugs used include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and somatostatin analogs. There are several drugs are being tested and in a recent study, Lutathera showed promising results as part of initial therapy for some neuroendocrine tumors including gastric tumors. The subjects who received Lu 177-dotatate plus octreotide lived almost three times as long without their cancer getting a worse stage. Several pharmaceutical companies and research institutes are developing innovative treatments to manage the tumor.
This section of the report covers the analysis of gastric neuroendocrine tumors drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for gastric neuroendocrine tumors pipeline drugs.
The drug molecules categories covered under gastric neuroendocrine tumors pipeline analysis include small molecule, monoclonal antibody, peptide, and polymer. Several therapeutic agents are under observation for treating gastric neuroendocrine tumors including VEGF monoclonal antibody, bevacizumab, and VEGF tyrosine kinase inhibitors. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gastric neuroendocrine tumors.
The EMR report for the gastric neuroendocrine tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric neuroendocrine tumors clinical trials:
The trial is designed to assess the safety of pasireotide LAR in combination with everolimus in patients with gastroenteropancreatic or neuroendocrine tumors. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase I.
The objective of the study is to assess the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced cancer. The trial is sponsored by Vedanta Biosciences, Inc. and is currently under phase I/II.
RECORDATI GROUP is developing the drug and is currently under phase IV. The study is being conducted to demonstrate the continuous use of pasireotide in patients who are taking pasireotide treatment in a Novartis-sponsored study.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Gastric Neuroendocrine Tumors Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gastric neuroendocrine tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within gastric neuroendocrine tumors pipeline insights.
Neuroendocrine Tumours Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share